Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now